Hang Xie

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi A live attenuated H1N1 M1 mutant provides broad cross-protection against influenza A viruses, including highly pathogenic A/Vietnam/1203/2004, in mice
    Hang Xie
    Laboratory of Respiratory Viral Diseases, Division of Viral Products, Office of Vaccine Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, Maryland, USA
    J Infect Dis 200:1874-83. 2009
  2. ncbi The compensatory G88R change is essential in restoring the normal functions of influenza A/WSN/33 virus matrix protein 1 with a disrupted nuclear localization signal
    Hang Xie
    Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, Maryland, USA
    J Virol 87:345-53. 2013
  3. ncbi Revisiting the 1976 "swine flu" vaccine clinical trials: cross-reactive hemagglutinin and neuraminidase antibodies and their role in protection against the 2009 H1N1 pandemic virus in mice
    Hang Xie
    Laboratory of Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Bethesda, Maryland 20892, USA
    Clin Infect Dis 53:1179-87. 2011
  4. ncbi Evaluating the vaccine potential of an influenza A viral hemagglutinin and matrix double insertion DNA plasmid
    Hang Xie
    Laboratory of Pediatric and Respiratory Virus Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, United States
    Vaccine 25:7649-55. 2007
  5. ncbi Immunogenicity and cross-reactivity of 2009-2010 inactivated seasonal influenza vaccine in US adults and elderly
    Hang Xie
    Laboratory of Respiratory Viral Diseases, Division of Viral Products, Office of Vaccine Research and Review, United States Food and Drug Administration, Bethesda, Maryland, United States of America
    PLoS ONE 6:e16650. 2011
  6. ncbi Cross-neutralizing antibodies to pandemic 2009 H1N1 and recent seasonal H1N1 influenza A strains influenced by a mutation in hemagglutinin subunit 2
    Wei Wang
    Laboratory of Immunoregulation, Division of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Bethesda, Maryland, United States of America
    PLoS Pathog 7:e1002081. 2011
  7. ncbi Mutations to A/Puerto Rico/8/34 PB1 gene improves seasonal reassortant influenza A virus growth kinetics
    Ewan P Plant
    Laboratory of Respiratory Viral Diseases, Division of Viral Products, Office of Vaccine Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, MD 20892, United States
    Vaccine 31:207-12. 2012
  8. ncbi Neutralizing and protective epitopes of the 2009 pandemic influenza H1N1 hemagglutinin
    Falko Schmeisser
    Division of Viral Products, Center for Biologics Evaluations and Research, Food and Drug Administration, Bethesda, MD, USA
    Influenza Other Respi Viruses 7:480-90. 2013
  9. ncbi Characterization of lentiviral pseudotypes with influenza H5N1 hemagglutinin and their performance in neutralization assays
    Wei Wang
    Center for Biologics Evaluation and Research, US Food and Drug Administration, Bethesda, MD 20892, United States
    J Virol Methods 165:305-10. 2010
  10. ncbi Intranasal immunization of the combined lipooligosaccharide conjugates protects mice from the challenges with three serotypes of Moraxella catarrhalis
    Dabin Ren
    Vaccine Research Section, National Institute on Deafness and Other Communication Disorders NIDCD, National Institutes of Health NIH, Rockville, Maryland, USA
    PLoS ONE 6:e29553. 2011

Collaborators

Detail Information

Publications10

  1. ncbi A live attenuated H1N1 M1 mutant provides broad cross-protection against influenza A viruses, including highly pathogenic A/Vietnam/1203/2004, in mice
    Hang Xie
    Laboratory of Respiratory Viral Diseases, Division of Viral Products, Office of Vaccine Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, Maryland, USA
    J Infect Dis 200:1874-83. 2009
    ..Our study suggests an alternative approach to attenuate wt influenza viruses for the development of a pandemic vaccine with broad cross-protection...
  2. ncbi The compensatory G88R change is essential in restoring the normal functions of influenza A/WSN/33 virus matrix protein 1 with a disrupted nuclear localization signal
    Hang Xie
    Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, Maryland, USA
    J Virol 87:345-53. 2013
    ..Our results suggested that restoring the normal functions of M1 was crucial for efficient virus replication...
  3. ncbi Revisiting the 1976 "swine flu" vaccine clinical trials: cross-reactive hemagglutinin and neuraminidase antibodies and their role in protection against the 2009 H1N1 pandemic virus in mice
    Hang Xie
    Laboratory of Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Bethesda, Maryland 20892, USA
    Clin Infect Dis 53:1179-87. 2011
    ..Approximately 45 million people in the United States were vaccinated against NJ/76 30 years ago, but the impact of this nationwide immunization on the current pandemic is largely unknown...
  4. ncbi Evaluating the vaccine potential of an influenza A viral hemagglutinin and matrix double insertion DNA plasmid
    Hang Xie
    Laboratory of Pediatric and Respiratory Virus Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, United States
    Vaccine 25:7649-55. 2007
    ..Furthermore, pHA/M1 immunization resulted in improved protection against both homologous and heterologous challenges...
  5. ncbi Immunogenicity and cross-reactivity of 2009-2010 inactivated seasonal influenza vaccine in US adults and elderly
    Hang Xie
    Laboratory of Respiratory Viral Diseases, Division of Viral Products, Office of Vaccine Research and Review, United States Food and Drug Administration, Bethesda, Maryland, United States of America
    PLoS ONE 6:e16650. 2011
    ..The pandemic specific cross-reactive antibodies strongly correlated with the post-vaccination HAI titers against the seasonal H3N2 vaccine strain in all subjects...
  6. ncbi Cross-neutralizing antibodies to pandemic 2009 H1N1 and recent seasonal H1N1 influenza A strains influenced by a mutation in hemagglutinin subunit 2
    Wei Wang
    Laboratory of Immunoregulation, Division of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Bethesda, Maryland, United States of America
    PLoS Pathog 7:e1002081. 2011
    ..These findings highlight a cross-neutralization determinant influenced by a point mutation in HA2 and suggest that HA2 may be evolving under direct or indirect immune pressure...
  7. ncbi Mutations to A/Puerto Rico/8/34 PB1 gene improves seasonal reassortant influenza A virus growth kinetics
    Ewan P Plant
    Laboratory of Respiratory Viral Diseases, Division of Viral Products, Office of Vaccine Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, MD 20892, United States
    Vaccine 31:207-12. 2012
    ....
  8. ncbi Neutralizing and protective epitopes of the 2009 pandemic influenza H1N1 hemagglutinin
    Falko Schmeisser
    Division of Viral Products, Center for Biologics Evaluations and Research, Food and Drug Administration, Bethesda, MD, USA
    Influenza Other Respi Viruses 7:480-90. 2013
    ....
  9. ncbi Characterization of lentiviral pseudotypes with influenza H5N1 hemagglutinin and their performance in neutralization assays
    Wei Wang
    Center for Biologics Evaluation and Research, US Food and Drug Administration, Bethesda, MD 20892, United States
    J Virol Methods 165:305-10. 2010
    ..These findings support continued development of HA-pseudotypes as a robust tool for analyzing sera in vaccine and serologic studies...
  10. ncbi Intranasal immunization of the combined lipooligosaccharide conjugates protects mice from the challenges with three serotypes of Moraxella catarrhalis
    Dabin Ren
    Vaccine Research Section, National Institute on Deafness and Other Communication Disorders NIDCD, National Institutes of Health NIH, Rockville, Maryland, USA
    PLoS ONE 6:e29553. 2011
    ..Lipooligosaccharide (LOS) based conjugate vaccines derived from individual serotype M. catarrhalis only showed partial protection coverage. A vaccine combining LOS conjugates of two or three serotypes might provide a broader protection...